dc.contributor.author | Rescigno, P | |
dc.contributor.author | Dolling, D | |
dc.contributor.author | Conteduca, V | |
dc.contributor.author | Rediti, M | |
dc.contributor.author | Bianchini, D | |
dc.contributor.author | Lolli, C | |
dc.contributor.author | Ong, M | |
dc.contributor.author | Li, H | |
dc.contributor.author | Omlin, AG | |
dc.contributor.author | Schmid, S | |
dc.contributor.author | Caffo, O | |
dc.contributor.author | Zivi, A | |
dc.contributor.author | Pezaro, CJ | |
dc.contributor.author | Morley, C | |
dc.contributor.author | Olmos, D | |
dc.contributor.author | Romero-Laorden, N | |
dc.contributor.author | Castro, E | |
dc.contributor.author | Saez, MI | |
dc.contributor.author | Mehra, N | |
dc.contributor.author | Smeenk, S | |
dc.contributor.author | Sideris, S | |
dc.contributor.author | Gil, T | |
dc.contributor.author | Banks, P | |
dc.contributor.author | Sandhu, SK | |
dc.contributor.author | Sternberg, CN | |
dc.contributor.author | De Giorgi, U | |
dc.contributor.author | De Bono, JS | |
dc.date.accessioned | 2020-06-03T09:18:35Z | |
dc.date.issued | 2020-04-01 | |
dc.identifier.citation | European urology oncology, 2020, 3 (2), pp. 176 - 182 | |
dc.identifier.issn | 2588-9311 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3673 | |
dc.identifier.eissn | 2588-9311 | |
dc.identifier.doi | 10.1016/j.euo.2019.06.008 | |
dc.description.abstract | BACKGROUND: Declines in prostate-specific antigen (PSA) levels at 12wk are used to evaluate treatment response in metastatic castration-resistant prostate cancer (mCRPC). PSA fall by ≥30% at 4wk (PSA4w30) has been reported to be associated with better outcome in a single-centre cohort study. OBJECTIVE: To evaluate clinical relevance of early PSA decline in mCRPC patients treated with next-generation hormonal treatments (NGHTs) such as abiraterone and enzalutamide. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective multicentre analysis. Eligible patients received NGHT for mCRPC between 6 January 2006 and 31 December 2017 in 13 cancer centres worldwide, and had PSA levels assessed at baseline and at 4 and/or 12wk after treatment. PSA response was defined as a ≥30% decline (progression as a ≥25% increase) from baseline. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Association with overall survival (OS) was analysed using landmark multivariable Cox regression adjusting for previous chemotherapy, including cancer centre as a shared frailty term. RESULTS AND LIMITATIONS: We identified 1358 mCRPC patients treated with first-line NGHT (1133 had PSA available at 4wk, and 948 at both 4 and 12wk). Overall, 583 (52%) had a PSA4w30; it was associated with longer OS (median: 23; 95% confidence interval [CI]: 21-25) compared with no change (median: 17; 95% CI: 15-18) and progression (median: 13; 95% CI: 10-15). A PSA12w30 was associated with lower mortality (median OS 22 vs 14; hazard ratio=0.57; 95% CI=0.48-0.67; p<0.001). PSA4w30 strongly correlated with PSA12w30 (ρ=0.91; 95% CI=0.90-0.92; p<0.001). In total, 432/494 (87%) with a PSA4w30 achieved a PSA12w30. Overall, 11/152 (7%) patients progressing at 4wk had a PSA12w30 (1% of the overall population). CONCLUSIONS: PSA changes in the first 4wk of NGHT therapies are strongly associated with clinical outcome from mCRPC and can help guide early treatment switch decisions. PATIENT SUMMARY: Prostate-specific antigen changes at 4wk after abiraterone/enzalutamide treatment are important to determine patients' outcome and should be taken into consideration in clinical practice. | |
dc.format | Print-Electronic | |
dc.format.extent | 176 - 182 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
dc.subject | Humans | |
dc.subject | Phenylthiohydantoin | |
dc.subject | Androstenes | |
dc.subject | Prostate-Specific Antigen | |
dc.subject | Treatment Outcome | |
dc.subject | Survival Analysis | |
dc.subject | Retrospective Studies | |
dc.subject | Time Factors | |
dc.subject | Male | |
dc.subject | Prostatic Neoplasms, Castration-Resistant | |
dc.title | Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2019-06-12 | |
rioxxterms.versionofrecord | 10.1016/j.euo.2019.06.008 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
rioxxterms.licenseref.startdate | 2020-04 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European urology oncology | |
pubs.issue | 2 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.publication-status | Published | |
pubs.volume | 3 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Prostate Cancer Targeted Therapy Group | |
dc.contributor.icrauthor | Rescigno, Pasquale | |
dc.contributor.icrauthor | De Bono, Johann | |